Synectics Share Discussion Threads

[attrader] 24/10/2012 08:28

Bought in here on ahead statement

[davebowler] 18/10/2012 08:19

Westhouse;
Strong Buy


SNX.L / 272.5p / £47.88m /



Likely % change in earnings forecasts: No Change





Buying opportunity

Synectics' share price has drifted back since the interim results in July while some of the comparator companies have seen their share prices rise. As the focus of investor attention switches to FY2013 in the coming months then we would expect that this share price underperformance will reverse. As has been flagged since it made the Indanet acquisition FY2013 would be the first year of a more meaningful profit contribution. This is reflected in the increase in our forecast PBT to £6.8m (30.4p of EPS) for FY2013 versus the £4.3m (19.1p of EPS) we expect for FY2012.

At our 350p target price Synectics now stands at a small P/E discount to the peer group (13.5x vs 14.6x) that we feel is unwarranted hence the reiteration of our Strong Buy recommendation.

[davebowler] 08/10/2012 14:22

Formerly Quadnetics (QDG)

[iloveit] 17/7/2012 16:12

UVEL,take a look epic UVEL this is where its happening ,new listing and BOOM !!!!

[papalpower] 07/11/2007 10:58

78p a share then it is.

[skiboy10] 22/10/2007 16:40

40K before the close over the offer @ 68p. Looks good for tomorrow.

[papalpower] 22/10/2007 16:28

Looking nice.

[skiboy10] 22/10/2007 09:37

Going back to £1?

[skiboy10] 22/10/2007 09:08

Looking good.

[skiboy10] 20/10/2007 01:26

OK. Should be a decent mark up from today's price though all being well.

[papalpower] 20/10/2007 01:24

No idea at all, I have been following this one only from time to time, and no feel for how someone else would value it.

[skiboy10] 20/10/2007 01:20

Any thoughts on the likely bid price?

[papalpower] 20/10/2007 01:10

Could be, depends on bid price, of course ;)

[skiboy10] 19/10/2007 22:00

That would be a yes then!

Synexus Clinical Res Response to price movement

RNS Number:0776G
Synexus Clinical Research PLC
19 October 2007


NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR
FROM ANY JURISDICTION WHERE IT IS UNLAWFUL TO DO SO


19 October 2007

Synexus Clinical Research PLC (the "Company")

Response to share price movement

In response to the recent movement in the Company's share price, the Company's
Board announces that it has received an approach and is currently in preliminary
discussions which may or may not lead to an offer for the entire issued and to
be issued share capital of the Company.

The Company has appointed Brewin Dolphin Limited to advise it on its strategic
options but there is no guarantee that an offer or any other transaction may
arise from this strategic review. Accordingly, shareholders are advised to take
no action at this stage but to await further developments.

Further announcements will be made as appropriate.

Pursuant to Rule 2.10 of the City Code, the Company announces that it has
23,154,172 ordinary shares of 10p each in issue (ISIN GB00B0L20P93).

Enquiries:

Synexus Clinical Research PLC
Malcolm Hughes, Chairman 07785 224008
Brewin Dolphin Limited (Financial and Nominated Adviser
to the Company)
Mark Brady 0845 270 8601
Richard Evans 0845 270 8602

The distribution of this announcement into jurisdictions other than the United
Kingdom may be restricted by law and therefore persons into whose possession
this announcement comes should inform themselves about and observe such
restrictions. Any failure to comply with the restrictions may constitute a
violation of the securities laws of any such jurisdiction.

The Directors of the Company accept responsibility for the information contained
in this announcement. To the best of knowledge and belief of the Directors, who
have taken all reasonable care to ensure such is the case, the information
contained in this announcement is in accordance with the facts and does not omit
anything likely to affect the import of such information.

Brewin Dolphin Limited is acting for the Company and no one else in connection
with this announcement and will not be responsible to anyone other than the
Company for providing the protections afforded to clients of Brewin Dolphin
Limited or for providing advice in relation to the contents of this
announcement.

Dealing Disclosure Requirements

Under the provisions of Rule 8.3 of the City Code on Takeovers and Mergers (the
"Code"), if any person is, or becomes, "interested" (directly or indirectly) in
1% or more of any class of "relevant securities" of the Company, all "dealings"
in any "relevant securities" of that company (including by means of an option in
respect of, or a derivative referenced to, any such "relevant securities") must
be publicly disclosed by no later than 3:30pm (London time) on the London
business day following the date of the relevant transaction. This requirement
will continue until the date on which the offer becomes, or is declared,
unconditional as to acceptances, lapses or is otherwise withdrawn or on which
the "offer period" otherwise ends. If two or more persons act together pursuant
to an agreement or understanding, whether formal or informal, to acquire an
"interest" in "relevant securities" of the Company, they will be deemed to be a
single person for the purpose of Rule 8.3.

Under the provisions of Rule 8.1 of the Code, all "dealings" in "relevant
securities" of the Company by the Company, or by any of their respective
"associates", must be disclosed by no later than 12:00 noon (London time) on the
London business day following the date of the relevant transaction.

A disclosure table, giving details of the companies in whose "relevant
securities" "dealings" should be disclosed, and the number of such securities in
issue, can be found on the Takeover Panel's website at
www.thetakeoverpanel.org.uk.

"Interests in securities" arise, in summary, when a person has long economic
exposure, whether conditional or absolute, to changes in the price of
securities. In particular, a person will be treated as having an "interest" by
virtue of the ownership or control of securities, or by the virtue of any option
in respect of, or derivative referenced to, securities.

Terms in quotation marks are defined in the Code, which can also be found on the
Panel's website. If you are in any doubt as to whether or not you are required
to disclose a "dealing" under Rule 8, you should consult the Panel.



This information is provided by RNS
The company news service from the London Stock Exchange

[skiboy10] 19/10/2007 15:41

Some life here today? Is this worth a punt?

[cat] 28/9/2007 07:27

read the prelims released in June.
Then read today's statement.
Wake up and smell the coffee.

[cat] 17/9/2007 14:12

spread the rest on the roses

[rabiddog] 14/9/2007 23:59

bailed out 60% of my small holding today.. only hope is a takeover for the remaining ?

[cat] 11/9/2007 16:24

Dynarod on the way

[smashingguy] 20/8/2007 10:22

This is a floater so will need extra gumption.

Colin